United States Uterine Fibroids Treatment Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Uterine Fibroids Treatment Devices Market Trends and Insights

Uterus-Preserving Treatment Preference

Patient preference for uterus-sparing care has changed referral behavior across the United States uterine fibroids treatment devices market, especially in health systems that now offer multiple procedural alternatives before hysterectomy is considered. A 2025 JAMA Network Open study showed that hysterectomy still represented 73.4% of fibroid treatment encounters, while UFE accounted for only 3.5%, which shows how much room remains for device-led treatment substitution.^{[1]JAMA Network Open, “Disparities in Utilization of Uterine Fibroid Embolization,” JAMA Network Open, jamanetwork.com.} This demand pattern is stronger among reproductive-age women who want symptom control without losing the uterus, and it matters even more in populations where fibroids appear earlier and with greater severity. In the United States uterine fibroids treatment devices market, that preference does not benefit only one modality because it lifts interest in RFA, embolization, and focused ultrasound at the same time. The result is a broader expansion path for manufacturers that can fit different patient profiles and care settings inside the same treatment journey.

Payer Expansion for Lap-RFA

Reimbursement has been one of the main commercial barriers for laparoscopic radiofrequency ablation, so payer coverage gains are now one of the most immediate growth supports for the United States uterine fibroids treatment devices market.^{[2]Medica, “Radiofrequency Ablation of Uterine Fibroids, Coverage Policy,” Medica, medica.com.} Medica’s published policy covers laparoscopic RFA for uterine fibroids, and ACOG Practice Bulletin 228 continues to support the procedure in the clinical decision framework used by providers and payers. As coverage improves, more cases can move into ASC and office-based settings, which lowers system friction for ablation adoption and broadens the commercial reach of the United States uterine fibroids treatment devices market. This shift also favors manufacturers that built compact or single-use tools rather than relying only on large installed-capital systems. CMS fee schedule rules and local coverage processes continue to shape procedure economics, so reimbursement execution remains central to near-term adoption even when clinical support is already in place.

Shift To Office and ASC Hysteroscopy Workflows

The movement of gynecologic hysteroscopy into office and ambulatory settings is becoming a practical growth driver for the United States uterine fibroids treatment devices market because it addresses cost pressure, scheduling delays, and patient convenience at the same time. Innovations Surgery Center in Rockville became the first ASC in the Mid-Atlantic region to offer robotic-assisted gynecologic surgery in January 2026, which shows that more complex fibroid procedures are moving beyond the hospital campus. Office-compatible hysteroscopic tools are also reducing setup burden and helping practices perform more procedures without a full operating-room infrastructure. In the United States uterine fibroids treatment devices market, this shift improves recurring procedure volume for vendors with disposables and procedure kits rather than one-time capital sales. The commercial effect is important because it changes revenue mix toward repeat consumable use and helps manufacturers build steadier account activity across community gynecology practices.

Hologic Portfolio Expansion After Sonata Integration

Hologic’s January 2025 acquisition of Gynesonics created the first dual-modality RFA portfolio in the United States uterine fibroids treatment devices market, combining laparoscopic and transcervical fibroid ablation under one commercial structure. The FDA then cleared Sonata System 2.2 in April 2025, which gave Hologic an updated platform for continued rollout after the integration.^{[3]U.S. Food and Drug Administration, “510(k) Premarket Notification K250705, Sonata Transcervical Fibroid Ablation System 2.2,” U.S. Food and Drug Administration, accessdata.fda.gov.} This portfolio now allows Hologic to address different patient pathways with one sales force, which strengthens its position in hospital systems and higher-volume community accounts. In the United States uterine fibroids treatment devices market, that kind of channel breadth is difficult for single-product competitors to match because physician access, training, and contracting all improve when the vendor can cover multiple care scenarios. The integration also narrows the time window for smaller challengers that previously competed against only one RFA modality at a time.

Uneven Reimbursement for MRgFUS

MRgFUS remains clinically relevant in the United States uterine fibroids treatment devices market, but commercial uptake is still limited because payers continue to classify the relevant CPT codes as investigational. Cigna, Blue Shield policies, and similar payer positions keep most volumes concentrated in academic centers where alternative funding or research pathways are more realistic. That gap between FDA approval and broad reimbursement slows market conversion even when the clinical value proposition is clear. In the United States uterine fibroids treatment devices market, this means non-invasive platforms have not translated their technology profile into wide commercial volume. Until a stronger cost-effectiveness case is accepted at scale, MRgFUS will likely remain more important in select centers than in broad routine care.

Fertility And Pregnancy Evidence Gaps

Evidence on fertility and pregnancy outcomes still shapes treatment choice in the United States uterine fibroids treatment devices market, especially for women who want future conception and are weighing minimally invasive options against myomectomy. A 2026 systematic review reported favorable fertility outcomes for laparoscopic and hysteroscopic myomectomy, while noting that ablative approaches still need stronger prospective reporting for fetal and pregnancy outcomes. That evidence gap drives conservative referral behavior, with physicians more likely to default to myomectomy when fertility remains a primary treatment objective. The effect is important because reproductive-age women represent a major treated population across the United States uterine fibroids treatment devices market. Manufacturers that can produce stronger multicenter fertility data will be better positioned to expand clinical acceptance and strengthen longer-term guideline support.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Technology: Ablation Disrupts the Surgical Baseline

Surgical techniques held 31.23% of the United States uterine fibroids treatment devices market share in 2025, which kept surgery as the largest technology category by revenue. That position remained supported by hysterectomy and myomectomy, which continue to offer definitive symptom resolution and strong institutional familiarity. A 2025 JAMA Network Open analysis found that hysterectomy represented 73.4% of fibroid treatment encounters nationally, which shows why surgical volume still anchors the technology mix. Broad insurance coverage and well-established hospital workflows also helped preserve surgical relevance across the United States uterine fibroids treatment devices market. Laparoscopic Techniques stayed between surgery and ablation in the adoption curve, with robotic-assisted myomectomy gaining ground as da Vinci access expands across outpatient sites.

The United States uterine fibroids treatment devices market size for ablation techniques is projected to grow at a 7.41% CAGR through 2031, making it the fastest-growing technology group. This growth reflects Hologic’s dual-platform RFA position after the Gynesonics integration and rising physician comfort with transcervical and laparoscopic workflows. The Sonata pivotal study reported a 2.2-day median return to normal activity, which aligns with patient preference for lower-disruption treatment paths. MRgFUS and USgHIFU remain part of the ablation opportunity, but reimbursement limits still restrict their contribution to the United States uterine fibroids treatment devices market. Embolization Techniques remain clinically established, and Merit’s Embosphere data continue to support strong physician loyalty in a consumable-driven part of the portfolio mix.

By Mode of Treatment: Minimally Invasive Routes Gain Procedural Share

Invasive treatment commanded 53.35% of the market in 2025, which shows that open and robotic-assisted surgery still formed the largest treatment pathway by revenue. This leadership persisted because many hospitals already had mature coding, credentialing, and surgical referral systems for hysterectomy and myomectomy. Reimbursement structure also matters, since payer policy can steer treatment selection even when alternative options are clinically available. In the United States, the uterine fibroids treatment devices industry kept invasive procedures deeply embedded in institutional practice, especially for patients with larger fibroids, more complex presentations, or physicians who prefer definitive surgical management. Robotic surgery added resilience to the invasive segment because hospitals and larger outpatient centers already understand the da Vinci workflow and have started extending it into ASC environments.

Minimally invasive treatment is forecast to grow at an 8.39% CAGR from 2026 to 2031, which puts it well above the overall rate of the United States uterine fibroids treatment devices market. The main drivers are hysteroscopic and laparoscopic procedures moving into ASCs and office settings, plus a stronger commercial scale for RFA systems after Hologic’s platform consolidation. Non-invasive Treatment remains the smallest mode, but it continues to attract strategic attention from health systems and device developers that want to compete on recovery time and patient experience. Profound Medical and Pro Familia reported 500 Sonalleve MRI-guided HIFU procedures at one center in February 2026, which adds useful real-world evidence for incision-free treatment models. The FDA’s higher evidentiary burden for MRgFUS under the PreMarket Approval path continues to slow iteration compared with the 510(k) route used by most RFA systems.

By End User: Hospitals Anchor Volume, ASCs Lead on Growth Rate

Hospitals retained 63.12% share in 2025, which kept them as the core end-user base in the United States uterine fibroids treatment devices market. Their lead reflects the concentration of interventional radiology suites, MRI capability for MRgFUS, and operating resources needed for higher-complexity surgical cases. Academic medical centers also remained important because they train physicians on Lap-RFA, robotic myomectomy, and evolving embolization workflows. Hospital-affiliated IR programs still handle most UFE activity, which keeps embolization volumes tied to larger urban systems rather than broadly distributed community sites. This hospital-centered structure continues to shape referral patterns, capital allocation, and procedure concentration across the United States uterine fibroids treatment devices market.

The United States uterine fibroids treatment devices market size for Ambulatory Surgical Centers is projected to grow at a 7.81% CAGR through 2031, making ASCs the fastest-growing end-user category. Favorable reimbursement for laparoscopic and hysteroscopic procedures and lower operating overhead are encouraging physicians to shift eligible cases into these settings. The January 2026 robotic gynecologic surgery launch at Innovations Surgery Center shows that even more advanced fibroid procedures are moving into freestanding outpatient environments. Office-based gynecology clinics are also gaining relevance, supported by products like Minerva Surgical’s HERizon Hysto-Kit, which was built to simplify in-office hysteroscopy setup. Interventional radiology centers remain more dependent on hospital affiliation because of capital and staffing needs, although telehealth consultations and mobile models are starting to improve access in harder-to-reach locations.

Geography Analysis

The Northeast and West Coast account for the largest share of the United States uterine fibroids treatment devices market size because they combine dense academic hospital networks, stronger commercial insurance penetration, and more established interventional radiology infrastructure. These regions also show strong demand for ablation and embolization procedures, especially in urban corridors where patients have access to multiple uterus-preserving treatment pathways. The prevalence gap reported between Black women and White women gives these metro markets a pronounced clinical demand base, particularly in cities with large Black and African American populations. Awareness activity around UFE and other uterus-sparing options has gained more traction in cities such as New York, Chicago, and Los Angeles, where referral depth and hospital capability are already present. The Cook Medical and Siemens Healthineers integrated iMRI Suite unveiled at SIR 2026 was aimed directly at this academic and high-resource tier, where imaging-led intervention is more feasible as the United States uterine fibroids treatment devices market evolves.

The South and Midwest present a less favorable access profile for the United States uterine fibroids treatment devices market, even though disease burden remains high in many communities. A very small share of UFE procedures occurred in rural hospitals, while more than 67% were concentrated in large urban facilities, which shows how strongly location still shapes treatment access. Registry-based reporting also showed that fewer than 1 in 6 US counties had a practicing SIR-registered physician, which continues to restrict UFE availability in rural and semi-rural areas. Telehealth-enabled consultations and mobile procedural programs are beginning to respond to this gap, but their reach remains limited in 2026.

The Mountain West and Pacific Northwest remain smaller in procedure volume, but they are important to the United States uterine fibroids treatment devices market because payer conditions and patient mix favor non-hysterectomy pathways. University-linked practices in California, Washington, and Colorado continue to act as early adopters for new ablation systems and imaging-integrated platforms. These geographies also benefit from a higher mix of privately insured patients, which tends to improve reimbursement conditions for newer procedures. As robotic gynecologic surgery expands in ASC settings and Intuitive Surgical continues to report strong procedure growth, the Pacific Coast is likely to contribute a disproportionate share of minimally invasive expansion within the United States uterine fibroids treatment devices market.